ABOUT ROCKETVAX
Rocketvax is a Swiss biotech developing next-generation treatment based on the live-attenuated virus technology. The company’s pipeline include a highly promising lead candidates to mitigate infection of existing and novel SARS-Cov-2 variants, sCPD9 and OTS. Rocketvax is part of the Swiss Rockets family, a leading biotech incubator.
ABOUT ROCKETVAX
SCIENCE
AT THE CORE
LEADERSHIP
EXCELLENCE
DRIVEN
BY INNOVATION
PROPRIETARY
IP
SUPERIOR INNOVATION AND PRODUCT-MARKET FIT
EVIDENCED BY US GOVERNMENT BACKING
up to $350m
received by Rocketvax in non-dilutive financing as part of the highly selective federal NextGen project led by the the National Institute of Allergy and Infectious Diseases (NIAID).
Project NextGen is a $5bn public initiative aimed at accelerating and streamlining the rapid development of the next generation of vaccines and treatments through public-private collaborations. As part of Project NextGen, NIAID will support a Phase 1 clinical study with Rocketvax’s RVX-sCPD9 vaccine in 2025.
REVOLUTIONARY BENEFITS
OF INTRANASAL DELIVERY
CAVITY
Induces potent local mucosal immunity at the site of virus entry
Reducing both virus infection and transmission
Contributing to the interruption of infection chains
Potential to curb any future COVID-19 pandemic
Ease of administration
TECHNOLOGY:
THE ROCKETVAX VACCINE PLATFORM
Rocketvax platform develops live-attenuated virus vaccines, which can be highly efficient against a variety of viral infections – offering significant future upside potential across several large-scale infectious diseases.
- Development of universal concept for live-attenuated vaccines
- Rational genetic design of generating attenuated viruses
- Concept expected to be applicable to a wide variety of viruses
CORONAVIRUSES
ALPHAVIRUSES
FLAVIVIRUSES
MERS-COV
INFLUENZA
SARBECOVIRUSES
COVID-19
HERPES
PNEUMOVIRUSES
LATEST NEWS
Download Our
Company Presentation
your name
your email
organization name